Literature DB >> 25698537

BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis.

Ye Yang1, Chunyan Gu, Chen Luo, Fei Li, Min Wang.   

Abstract

Multiple myeloma (MM) is the second most common hematopoietic malignancy characterized by plasma cell proliferative disorder. In this study, we disclosed that expression of BUB1B significantly increased in high-risk myeloma patients especially in the most aggressive myeloma genetic subgroups of proliferation. Increased BUB1B expression promotes MM cell proliferation. Mechanism study showed that BUB1B expression was highly correlated to CDC20 and CCNB1/2 expression in MM cells, leading to increased MM cell proliferation. Therefore, BUB1B may be a potential target for MM treatment especially for high-risk MM patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25698537     DOI: 10.1007/s12032-015-0542-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  19 in total

1.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

2.  Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma.

Authors:  Ye Yang; Jumei Shi; Zhimin Gu; Mohamed E Salama; Satyabrata Das; Erik Wendlandt; Hongwei Xu; Junwei Huang; Yi Tao; Mu Hao; Reinaldo Franqui; Dana Levasseur; Siegfried Janz; Guido Tricot; Fenghuang Zhan
Journal:  Cancer Res       Date:  2015-01-14       Impact factor: 12.701

Review 3.  Advances in treatment for relapses and refractory multiple myeloma.

Authors:  Tiffany Richards; Donna Weber
Journal:  Med Oncol       Date:  2010-03-06       Impact factor: 3.064

4.  Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival.

Authors:  Masayoshi Shichiri; Keigo Yoshinaga; Hisashi Hisatomi; Kenichi Sugihara; Yukio Hirata
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

5.  Peperotetraphin inhibits the proliferation of human prostate cancer cells via induction of cell cycle arrest and apoptosis.

Authors:  Yunzhi Li; Ning He; Chengwu Zhai
Journal:  Med Oncol       Date:  2015-01-13       Impact factor: 3.064

6.  Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.

Authors:  Lei Shi; Siqing Wang; Maurizio Zangari; Hongwei Xu; Thai M Cao; Chunjiao Xu; Yong Wu; Fang Xiao; Yinghong Liu; Ye Yang; Mohamed Salama; Guiyuan Li; Guido Tricot; Fenghuang Zhan
Journal:  Oncotarget       Date:  2010-05

7.  Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer--association with tumour cell proliferation.

Authors:  Heike Grabsch; Shinsuke Takeno; Wendy J Parsons; Natalja Pomjanski; Alfred Boecking; Helmut Erich Gabbert; Wolfram Mueller
Journal:  J Pathol       Date:  2003-05       Impact factor: 7.996

8.  Differential promoter methylation may be a key molecular mechanism in regulating BubR1 expression in cancer cells.

Authors:  Hye-Young Park; Yoon-Kyung Jeon; Hyun-Jin Shin; Il-Jin Kim; Hio-Chung Kang; Sook-Jung Jeong; Doo-Hyun Chung; Chang-Woo Lee
Journal:  Exp Mol Med       Date:  2007-04-30       Impact factor: 8.718

Review 9.  Treatment of newly diagnosed multiple myeloma: advances in current therapy.

Authors:  Shaji Kumar
Journal:  Med Oncol       Date:  2009-12-25       Impact factor: 3.064

10.  NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma.

Authors:  Ye Yang; Wen Zhou; Jiliang Xia; Zhimin Gu; Erik Wendlandt; Xin Zhan; Siegfried Janz; Guido Tricot; Fenghuang Zhan
Journal:  Oncotarget       Date:  2014-12-15
View more
  11 in total

1.  Prognostic Prediction Using a Stemness Index-Related Signature in a Cohort of Gastric Cancer.

Authors:  Xiaowei Chen; Dawei Zhang; Fei Jiang; Yan Shen; Xin Li; Xueju Hu; Pingmin Wei; Xiaobing Shen
Journal:  Front Mol Biosci       Date:  2020-09-04

2.  MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.

Authors:  Chunyan Gu; Lang Feng; Hailin Peng; Hongbao Yang; Zhenqing Feng; Ye Yang
Journal:  Oncotarget       Date:  2016-01-26

3.  Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells.

Authors:  Susanne Lub; Anke Maes; Ken Maes; Kim De Veirman; Elke De Bruyne; Eline Menu; Karel Fostier; Alboukadel Kassambara; Jérôme Moreaux; Dirk Hose; Xavier Leleu; Randall W King; Karin Vanderkerken; Els Van Valckenborgh
Journal:  Oncotarget       Date:  2016-01-26

Review 4.  The therapeutic potential of cell cycle targeting in multiple myeloma.

Authors:  Anke Maes; Eline Menu; Kim De Veirman; Ken Maes; Karin Vand Erkerken; Elke De Bruyne
Journal:  Oncotarget       Date:  2017-06-28

5.  Kinome expression profiling to target new therapeutic avenues in multiple myeloma.

Authors:  Hugues de Boussac; Angélique Bruyer; Michel Jourdan; Anke Maes; Nicolas Robert; Claire Gourzones; Laure Vincent; Anja Seckinger; Guillaume Cartron; Dirk Hose; Elke De Bruyne; Alboukadel Kassambara; Philippe Pasero; Jérôme Moreaux
Journal:  Haematologica       Date:  2019-07-09       Impact factor: 9.941

6.  BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability.

Authors:  Xiaozhu Tang; Mengjie Guo; Pinggang Ding; Zhendong Deng; Mengying Ke; Yuxia Yuan; Yanyan Zhou; Zigen Lin; Muxi Li; Chunyan Gu; Xiaosong Gu; Ye Yang
Journal:  Signal Transduct Target Ther       Date:  2021-10-07

Review 7.  CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies.

Authors:  Samantha Bruno; Andrea Ghelli Luserna di Rorà; Roberta Napolitano; Simona Soverini; Giovanni Martinelli; Giorgia Simonetti
Journal:  J Exp Clin Cancer Res       Date:  2022-04-30

Review 8.  Chromosomal instability and acquired drug resistance in multiple myeloma.

Authors:  Wang Wang; Yi Zhang; Ruini Chen; Zhidan Tian; Yongpin Zhai; Siegfried Janz; Chunyan Gu; Ye Yang
Journal:  Oncotarget       Date:  2017-09-11

9.  Transcriptome sequencing to detect the potential role of long non-coding RNAs in bovine mammary gland during the dry and lactation period.

Authors:  Bing Yang; Beilei Jiao; Wei Ge; Xiaolan Zhang; Shanhe Wang; Hongbo Zhao; Xin Wang
Journal:  BMC Genomics       Date:  2018-08-13       Impact factor: 3.969

10.  BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway.

Authors:  Jiannan Qiu; Shaopeng Zhang; Peng Wang; Hao Wang; Bowen Sha; Hao Peng; Zheng Ju; Jianhua Rao; Ling Lu
Journal:  Cancer Med       Date:  2020-09-25       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.